Company Snapshot: HSP  Print This Story  Email This Story  Save this Link View PR Newswire's RSS Feed  Blogs Discussing this News Release  Search Blogs that Mention this News Release  Click this link to view linked Bookmarking Services Click this link to view linked Blogging Services


Hospira Highlights Strategic Initiatives at Its 2008 Annual Meeting of Shareholders

   Like the name Hospira, the logo is unique, differentiating and contemporary. The arc highlights the word "spira" in the name, reinforcing Hospira's aspiration to be the world's leading hospital products provider and highlighting the spirit and inspiration of the employees that guide the company. (PRNewsFoto)

LAKE FOREST, IL USA
                   - Shareholders Ratify Both Proposals -

    LAKE FOREST, Ill., May 13 /PRNewswire-FirstCall/ -- Hospira, Inc.
(NYSE: HSP), a leading global specialty pharmaceutical and medication
delivery company, today held its 2008 Annual Meeting of Shareholders in
Wilmington, Del. The agenda included votes on two proposals and a brief
update on the company's progress and strategy.

    "Our 2007 results point to the success of our strategies of investing
for growth, and improving operating margins and cash flow," said
Christopher B. Begley, chairman and chief executive officer, Hospira. "It's
through our disciplined focus on executing these strategies that Hospira
has become the growing, profitable company it is today and is positioned
for continued success going forward."


During the annual meeting, shareholders: -- elected the following directors for three-year terms expiring in 2011: Irving W. Bailey, II, Ronald A. Matricaria and Jacque J. Sokolov, M.D.; and -- ratified the appointment of Deloitte & Touche LLP as Hospira's auditors for 2008. A full description of the above matters was included in Hospira's proxy statement related to the meeting. The proxy statement is available on Hospira's Web site at http://www.hospirainvestor.com, as are Begley's remarks made at today's meeting. About Hospira Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at http://www.hospira.com.
Private Securities Litigation Reform Act of 1995 -- A Caution Concerning Forward-Looking Statements This press release contains statements that may be construed as forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K and the subsequent Form 10-Q, filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.
SOURCE Hospira, Inc.




Back to Topback to top

Related links:
  • http://www.hospira.com
    Photo Notes:http://www.newscom.com/cgi-bin/prnh/20040503/HSPLOGO
    AP Archive: http://photoarchive.ap.org
    PRN Photo Desk, photodesk@prnewswire.com
    CONTACT:
    Media, Stacey Eisen, +1-224-212-2276, or
    Financial Community, Ruth Venning, +1-224-212-2774, both of
    Hospira, Inc.